Foley Hoag LLP advised Alloy Therapeutics on the deal. Alloy Therapeutics, a biotechnology ecosystem company, announced a $42 million Series D financing round led by its existing...
You must be a Standard 1 Year member to access this content.
Foley Hoag LLP represented Vergent Bioscience, Inc. on the deal. Vergent Bioscience, Inc. (“Vergent”), a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced a $21.5 million Series...
You must be a Standard 1 Year member to access this content.
Foley Hoag advised RedShift BioAnalytics on the deal. RedShift BioAnalytics Inc. (RedShiftBio), a company providing next-generation platform technology enabling measurement of previously undetectable structure changes in...
You must be a Standard 1 Year member to access this content.
Foley Hoag LLP advised Alloy Therapeutics on the deal. Alloy Therapeutics announced a $75 million Series C Financing. Proceeds from the Series C financing will support the...
You must be a Standard 1 Year member to access this content.
